Alzheimer’s disease (AD) affects women more than men and consequently has been associated with menopause. Tibolone (TIB) has been used as a hormone replacement therapy to alleviate climacteric symptoms. Neuroprotective effects of TIB have also been reported in some animal models.
Objective:
This study aimed to assess the effect of TIB on memory and Aβ peptides and tau protein content in the hippocampus and cerebellum of transgenic 3xTgAD ovariectomized mice.
Methods:
Three-month-old female mice were ovariectomized. Ten days after surgery, animals were divided into four groups: wild-type (WT)+vehicle; WT+TIB (1 mg/kg); 3xTgAD+vehicle; and 3xTgAD+TIB (1 mg/kg). TIB was administered for three months, and memory was evaluated using the object-in-context recognition task. Subsequently, animals were decapitated, and the hippocampus and cerebellum were dissected. Using commercial ELISA kits, these brain structures were homogenized in a PBS buffer for quantifying Aβ40 and Aβ42 and phosphorylated and total tau.
Results
A long-term memory deficit was observed in the 3xTgAD+vehicle group. In contrast, TIB treatment improved long-term memory in the 3xTgAD+TIB group than those treated with vehicle (p < 0.05). Furthermore, TIB treatment decreased Aβ and tau content in the hippocampus of 3xTgAD mice compared to vehicle-treated groups (p < 0.05). No significant changes were observed in the cerebellum.
Conclusion:
Chronic treatment with TIB showed neuroprotective effects and delayed AD neuropathology in the 3xTgAD mice. Our results support hormone replacement therapy with TIB in menopausal women for neuroprotection.
FörstlH, KurzcA (1999) Clinical features of Alzheimer’s disease. . Eur Arch Psychiatry Clin Neurosci249, 288–290.
3.
HebertLE, ScherrPA, BieniasJL, BennettDA, EvansDA (2003) Alzheimer disease in the US population: prevalence estimates using the 2000 Census. . Arch Neurol60, 1119–1122.
ChengYJ, LinCH, LaneHY (2021) From menopause to neurodegeneration— molecular basis and potential therapy. . Int J Mol Sci22, 8654.
10.
Paganini-HillA, HendersonVW (1994) Estrogen deficiency and risk of Alzheimer’s disease in women. . Am J Epidemiol140, 256–261.
11.
TangMX, JacobsD, SternY, MarderK, SchofieldP, GurlandB, AndrewsH, MayeuxR (1996) Effect of oestrogen during menopause on risk and age at onset of Alzheimer’s disease. Lancet348, 429–432.
12.
KawasC, ResnickS, MorrisonA, BrookmeyerR, CorradaM, ZondermanA, BacalC, LingleDD, MetterE (1997) A prospective study of estrogen replacement therapy and the risk of developing Alzheimer’s disease: the Baltimore Longitudinal Study of Aging. . Neurology48, 1517–1521.
13.
YangZ, HuY, ZhangJ, XuL, ZengR, KangD (2017) Estradiol therapy and breast cancer risk in perimenopausal and postmenopausal women: a systematic review and meta-analysis. . Gynecol Endocrinol33, 87–92.
14.
D’AlonzoM, BounousVE, VillaM, BigliaN (2019) Current evidence of the oncological benefit-risk profile of hormone replacement therapy. . Medicina (Kaunas)55, 573.
15.
CampisiR, MarengoFD (2007) Cardiovascular effects of tibolone: a selective tissue estrogenic activity regulator. . Cardiovasc Drug Rev25, 132–145.
16.
KloosterboerHJ (2001) Tibolone: a steroid with a tissue-specific mode of action. . J Steroid Biochem Mol Biol76, 231–238.
17.
VerheulHAM, TimmerCJ, Van IerselMLPS, DelbressineLPC, KloosterboerHJ (2007) Pharmacokinetic parameters of tibolone and metabolites in plasma, urine, feces, and bile from ovariectomized cynomolgus monkeys after a single dose or multiple doses of tibolone. Drug Metab Dispos35, 1112–1118.
18.
EcheverríaV, EcheverríaF, BarretoGE, EcheverríaJ, MendozaC (2021) Estrogenic plants: to prevent neurodegeneration and memory loss and other symptoms in women after menopause. . Front Pharmacol12, 644103.
19.
GallagherJC, BaylinkDJ, FreemanR, McClungM (2001) Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. . J Clin Endocrinol Metab86, 4717–4726.
20.
Pinto-Almazan R, Rivas-ArancibiaS, Farfan-GarcyaED, Rodríguez-MartínezE, Guerra-AraizaC (2014) Neuroprotective effects of tibolone against oxidative stress induced by ozone exposure. . Rev Neurol58, 441–449.
21.
Farfan-GarcyaED, Castillo-HernandezC, Pinto-AlmazanR, Rivas-ArancibiaS, GallardoJM, Guerra-AraizaC (2014) Tibolone prevents oxidation and ameliorates cholinergic deficit induced by ozone exposure in the male rat hippocampus. . Neurochem Res39, 1776–1786.
22.
Espinosa-RayaJ, Neri-GómezT, Orozco-SuarezS, CamposMG, Guerra-AraizaC (2012) Chronic administration of tibolone modulates anxiety-like behavior and enhances cognitive performance in ovariectomized rats. . Horm Behav61, 76–83.
23.
Neri-GómezT, Espinosa-RayaJ, Díaz-CintraS, Segura-UribeJ, Orozco-SuarezS, GallardoJM, Guerra-AraizaC (2017) Tibolone modulates neuronal plasticity through regulating Tau, GSK3β/Akt/PI3K pathway and CDK5 p35/p25 complexes in the hippocampus of aged male mice. . Neural Regen Res12, 588–595.
24.
Pinto-AlmazanR, Segura-UribeJJ, Soriano-UrsúaMA, Farfan-GarcyaED, GallardoJM, Guerra-AraizaC (2018) Effect of tibolone pretreatment on kinases and phosphatases that regulate the expression and phosphorylation of Tau in the hippocampus of rats exposed to ozone. . Neural Regen Res13, 440–448.
25.
RamsaranAI, WestbrookSR, StantonME (2016) Ontogeny of object-in-context recognition in the rat. . Behav Brain Res298, 37–47.
26.
BalderasI, Rodríguez-OrtiCJ, Salgado-TondaP, Chavez-HurtadoH, McGaughJL, Bermudez-RattoniF (2008) The consolidation of object and context recognition memory involve different regions of the temporal lobe. . Learn Mem15, 618–624.
27.
Del Río JP, MolinaS, Hidalgo-LanussaO, Garcia-SeguraLM, BarretoGE (2020) Tibolone as hormonal therapy and neuroprotective agent. . Trends Endocrinol Metab31, 742–759.
28.
Estrada-CruzNA, Manuel-ApolinarL, Segura-UribeJJ, Almanza-Perez JC, Fortis-BarreraÁA, Orozco-SuarezS, Bautista-PobletG, Coyoy-SalgadoA, Guerra-AraizaC (2022) Short-term administration of tibolone reduces inflammation and oxidative stress in the hippocampus of ovariectomized rats fed high-fat and high-fructose. . Nutr Neurosci13, 1–15.
29.
IshuninaTA, SwaabDF (2001) Increased expression of estrogen receptor alpha and beta in the nucleus basalis of Meynert in Alzheimer’s disease. . Neurobiol Aging22, 417–426.
30.
IshuninaTA, SwaabDF (2003) Increased neuronal metabolic activity and estrogen receptors in the vertical limb of the diagonal band of Broca in Alzheimer’s disease: relation to sex and aging. . Exp Neurol183, 159–172.
LaiYJ, ZhuBL, SunF, LuoD, MaYL, LuoB, TangJ, XiongMJ, LiuL, LongY, HuXT, HeL, DengXJ, ZhangJH, YangJ, YanZ, ChenGJ (2019) Estrogen receptor α promotes Cav1.2 ubiquitination and degradation in neuronal cells and in APP/PS1 mice. Aging Cell18, e12961.
33.
CarrollJC, RosarioER, ChangL, StanczykFZ, OddoS, LaFerlaFM, PikeCJ (2007) Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. J Neurosci2713357–13365
34.
CarrollJC, RosarioER, VillamagnaA, PikeCJ (2010) Continuous and cyclic progesterone differentially interact with estradiol in the regulation of Alzheimer-like pathology in female 3xTransgenic-Alzheimer’s disease mice. Endocrinology151, 2713–2722.
35.
LandgrenMB, HelmondFA, EngelenS (2005) Tibolone relieves climacteric symptoms in highly symptomatic women with at least seven hot flushes and sweats per day. . Maturitas50, 222–230.
36.
CarswellHV, MacraeIM, GallagherL, HarropE, HorsburghKJ (2004) Neuroprotection by a selective estrogen receptor beta agonist in a mouse model of global ischemia. Am J Physiol Heart Circ Physiol287, H1501–H1504.
37.
MancinoDNJ, LimaA, RoigP, García SeguraLM, De NicolaAF, GarayLI (2022) Tibolone restrains neuroinflammation in mouse experimental autoimmune encephalomyelitis. J Neuroendocrinol34, e13078.
38.
GibbsRB, NelsonD, AnthonyMS, ClarksonTB (2002) Effects of long-term hormone replacement and of tibolone on choline acetyltransferase and acetylcholinesterase activities in the brains of ovariectomized, cynomolgus monkeys. . Neuroscience113, 907–914.
39.
QiuJ, BoschMA, RnnekleivOK, KloosterboerHJ, KellyMJ (2008) Tibolone rapidly attenuates the GABAB response in hypothalamic neurons. . J Neuroendocrinol20, 1310–1318.
40.
Beltran-Campos V, Díaz-RuizA, Padilla-GómezE, Aguilar ZavalaH, RíosC, DíazCintra S (2015) Effect of tibolone on dendritic spine density in the rat hippocampus.. Neurologya30, 401–406.
41.
VergouwenMD, AndersonRE, MeyerFB (2000) Gender differences and the effects of synthetic exogenous and non-synthetic estrogens in focal cerebral ischemia. Brain Res878, 88–97.
42.
Crespo-CastrilloA, Yanguas-Casบs N, ArevaloMA, AzcoitiaI, BarretoGE, Garcia-SeguraLM (2018) The synthetic steroid tibolone decreases reactive gliosis and neuronal death in the cerebral cortex of female mice after a stab wound injury. . Mol Neurobiol55, 8651–8667.
43.
Acaz-FonsecaE, Sanchez-GonzalezR, AzcoitiaI, ArevaloMA, Garcia-SeguraLM (2014) Role of astrocytes in the neuroprotective actions of 17β-estradiol and selective estrogen receptor modulators. . Mol Cell Endocrinol389, 48–57.
44.
Avila-RodriguezM, Garcia-SeguraLM, Hidalgo-LanussaO, BaezE, GonzalezJ, BarretoGE (2016) Tibolone protects astrocytic cells from glucose deprivation through a mechanism involving estrogen receptor beta and the upregulation of neuroglobin expression. . Mol Cell Endocrinol433, 35–46.
45.
Fernaud-EspinosaI, Nieto-SampedroM, BovolentaP (1993) Differential activation of microglia and astrocytes in aniso- and isomorphic gliotic tissue. . Glia8, 277–291.
46.
Hidalgo-LanussaO, Ávila-RodriguezM, Baez-JuradoE, ZamudioJ, EcheverriaV, Garcia-SeguraLM, BarretoGE (2018) Tibolone reduces oxidative damage and inflammation in microglia stimulated with palmitic acid through mechanisms involving estrogen receptor beta. . Mol Neurobiol55, 5462–5477.
47.
Coyoy-SalgadoA, Segura-UribeJJ, Manuel GallardoJ, Estrada-CruzNA, Camacho-ArroyoI, Guerra-AraizaC (2020) Tibolone regulates systemic metabolism and the expression of sex hormone receptors in the central nervous system of ovariectomised rats fed with high-fat and high-fructose diet. . Brain Res1748, 147096.
48.
WuJ, ZhuY, WuJ (2008) Effects of estrogen and estrogenic compounds on cognition in ovariectomized rats. . Climacteric11, 212–220.
49.
GourasGK, OlssonTT, HanssonO (2015)
β-Amyloid peptides and amyloid plaques in Alzheimer’s disease. . Neurotherapeutics12, 3–11.
50.
HaassC, SelkoeDJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. . Nat Rev Mol Cell Biol8, 101–112.
51.
HymanBT, Van HoesenGW, DamasioAR, BarnesCL (1984) Alzheimer’s disease: cell-specific pathology isolates the hippocampal formation. . Science225, 1168–1170.
52.
WestMJ, ColemanPD, FloodDG, TroncosoJC (1994) Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer’s disease. . Lancet344, 769–772.
53.
ScheffSW, PriceDA, SchmittFA, DeKoskyST, MufsonEJ (2007) Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. . Neurology68, 1501–1508.
54.
MiniaciMC, De LeonibusE (2018) Missing the egocentric spatial reference: a blank on the map. . F1000Res7, 168.
55.
HoxhaE, LippielloP, ZurloF, BalboI, SantamariaR, TempiaF, MiniaciMC (2018) The emerging role of altered cerebellar synaptic processing in Alzheimer’s disease. . Front Aging Neurosci10, 396.
56.
JacobsHIL, HopkinsDA, MayrhoferHC, BrunerE, van LeeuwenFW, RaaijmakersW, SchmahmannJD (2018) The cerebellum in Alzheimer’s disease: evaluating its role in cognitive decline. . Brain141, 37–47.
57.
Sepúlveda-FallaD, MatschkeJ, BernreutherC, HagelC, PuigB, VillegasA, GarciaG, ZeaJ, Gomez-MancillaB, FerrerI, LoperaF, GlatzelM (2011) Deposition of hyperphosphorylated tau in cerebellum of PS1 E280A Alzheimer’s disease. . Brain Pathol21, 452–463.
MevelK, ChetelatG, EustacheF, DesgrangesB (2011) The default mode network in healthy aging and Alzheimer’s disease. . Int J Alzheimers Dis2011, 535816.
60.
GuoCC, TanR, HodgesJR, HuX, SamiS, HornbergerM (2016) Network-selective vulnerability of the human cerebellum to Alzheimer’s disease and frontotemporal dementia. . Brain139, 1527–1538.
61.
AggarwalNT, WilsonRS, BeckTL, BieniasJL, BennettDA (2006) Motor dysfunction in mild cognitive impairment and the risk of incident Alzheimer disease. Arch Neurol63, 1763–1769.
62.
SjögrenM, DavidssonP, GottfriesJ, VandersticheleH, EdmanA, VanmechelenE, WallinA, BlennowK (2001) The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer’s disease, reflecting a common pathophysiological process. . Dement Geriatr Cogn Disord12, 257–264.
